SAN CARLOS, CA -- (Marketwired) -- 05/17/17 --
- Poster to highlight new interim data from cohort one of ongoing Phase 2 trial of LN-144 in patients with metastatic melanoma
- First data readout for Lion-sponsored clinical trial investigating TIL
Lion Biotechnologies, Inc.(NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new interim data from the first cohort of its ongoing Phase 2 study of LN-144 for the treatment of metastatic melanoma will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 2-6, 2017.
"We are very encouraged by this data as we have now demonstrated that we can manufacture TIL at our contract manufacturing organization partners and dose patients at multiple clinical sites with consistent results compared to available literature. The patients enrolled in this study are more treatment experienced than those enrolled in most of the previously published TIL clinical studies. The enrolled patients disclosed in the abstract have advanced metastatic melanoma, all refractory to both anti-PD-1 and CTLA-4 with a median of 3 prior therapies," said Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Lion Biotechnologies. "We will be reporting data from additional patients in the current cohort at the conference as well."
Poster Title: Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-treated Metastatic Melanoma Patients Following Checkpoint Therapy
Poster Session Title: Developmental Therapeutics -- Immunotherapy
Poster Board Number: 140
Date & Time: Monday, June 5, 2017 from 8:00 a.m. to 11:00 a.m. CT (9:00 a.m. to 12:00 p.m. ET)
Abstract Number: 3045
Location: Hall A
First author: Amod Sarnaik, MD
The data in the published abstract is from nine patients in cohort one who were infused as of January 31, 2017. These advanced metastatic melanoma patients are a median age of 56 and all had prior anti-PD1 as well as anti-CTLA4 therapy and 67 percent had received three or more prior therapies. The results show:
- 33% objective response rate
- Responses were observed in patients with tumors carrying wild type or BRAF mutations
- Eight of nine patients received all six doses of IL-2 per protocol
- The most common (≥3 patients) non-hematologic grade 3-4 TEAE was hypophosphatemia
- No neurotoxicity of grade 3 or higher was reported
- There were no deaths or discontinuations due to SAEs related to study treatment
The accepted abstract is available online on ASCO's website at http://am.asco.org.
About Lion Biotechnologies, Inc.
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with refractory metastatic melanoma, metastatic squamous cell carcinoma of the head and neck, and metastatic cervical carcinoma. For more information, please visit http://www.lionbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" regarding, among other things, the Company's clinical plans. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate, or if known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections. A further list and description of Lion Biotechnologies risks, uncertainties and other factors can be found in Lion Biotechnologies, Inc. most recent Annual Report on Form 10-K and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.lionbio.com. Any forward-looking statement made in this release speaks only as of the date of this release. Lion Biotechnologies, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Source: Lion Biotechnologies, Inc.
